Synergy Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 85   

Articles published

SGYP 9.87 +0.13 (1.34%)
price chart
Why Synergy Pharmaceuticals, Inc. Shares Are Surging Higher
However, before investors get too excited, they should remember that Synergy Pharmaceuticals is a clinical-stage company without any products on the market or revenue. Also, investors need to remember that there's no guarantee that an FDA approval ...
Synergy Pharma's constipation drug succeeds in late-stage study  Reuters
Synergy Soars as Drug That May Spur Takeover Beats Expectations  Bloomberg
Zacks Rating on Synergy Pharmaceuticals, Inc.
Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) remains a strong buy in the latest set of rankings. The shares has received an average rating of 1 by 2 analysts.
Shares of Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) Sees Large Outflow ...  Insider Trading Report
Company Shares of Synergy Pharmaceuticals, Inc. Rally 12.9%  OTC Outlook
Why Chubb Corp (CB), CalAmp Corp. (CAMP) and Synergy Pharmaceuticals Inc ...
U.S. markets opened much higher this morning, but then pared some of those gains over the rest of the day. Traders were again focused on the developments between Greece and its creditors.
Active Trending Stocks: Synergy Pharmaceuticals Inc (NASDAQ:SGYP), Franklin ...
Synergy Pharmaceuticals Inc, declared that its Chairman and Chief Executive Officer, Gary S. Jacob, Ph.D., will present a corporate update at the Cantor Fitzgerald Healthcare Conference on Wednesday, July 8, 2015 at 2:30 p.m.
Stocks Hitting 52-Week Highs
Synergy Pharmaceuticals Inc (NASDAQ: SGYP) shares reached a new 52-week high of $9.895. Synergy Pharmaceuticals shares have jumped 149.10 percent over the past 52 weeks, while the S&P 500 index has gained 5.35 percent in the same period.
Friday's Trade Stocks Highlights: Synergy Pharmaceuticals Inc (NASDAQ:SGYP ...
Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development of drugs to treat gastrointestinal (GI) disorders and diseases.
Wednesday's Morning Insights: Synergy Pharmaceuticals Inc (SGYP ...
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) has increased $5.78 in mid-day trading to $8.78 as the company announced two new additions to its Board of Directors.
Analyst Price Target Update on Synergy Pharmaceuticals, Inc.  Insider Trading Report
Synergy Pharmaceuticals Appoints Timothy Callahan and Richard Daly to Board ...  MarketWatch
Biotech Beat: MannKind Corporation (MNKD), Gilead Sciences, Inc. (GILD ...
Well, the Greek Debt Crisis has come to a conclusion, a default; and US stocks seem to be back to normal. This leaves us with a bit of a mixed market in biotech today.
Analyst Rating Update on Synergy Pharmaceuticals, Inc.
As many as 2 brokerage firms have rated Synergy Pharmaceuticals Inc (NASDAQ:SGYP) at 1. Research Analysts at Zacks have ranked the company at 2, suggesting the traders with a rating of buy for the short term.
Large Outflow of Money Witnessed in Synergy Pharmaceuticals, Inc.  Money Flow Index
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) Canaccord Genuity initiated ...
Synergy Pharmaceuticals has four Phase 3 trials maturing over the next 12 months in chronic idiopathic constipation (CIC) and constipation-predominant irritable bowel syndrome (IBS-C), all of which are predicted to have a high likelihood of success and ...
Update: Synergy Pharmaceuticals, Inc. Short Interest Increases by 8.5%  Money Flow Index
Small Cap Stocks Roundup - Synergy Pharmaceuticals (SGYP), Harmony Gold ...  Techsonian (press release)